Clinical trial · Interventional
Oncology Acute Care Follow-up Intervention Study
A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health. Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends. After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Follow-up messaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control Arm (Usual Care)
- description
- Patients receive standard hospital discharge instructions without additional messaging Patients in the control arm who experience a subsequent cancer treatment-related ED visit without documented OAC engagement will be crossed over to the intervention arm.
- type
- EXPERIMENTAL
- label
- Intervention Arm
- description
- Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge.
- interventionNames
- Other: Follow-up messaging
Primary outcomes (1)
- measure
- Time to the next cancer treatment related ED visit.
- timeFrame
- 2 years maximum
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Active cancer diagnosis * Actively receiving chemotherapy treatment * ED Arrival within 30 days of chemotherapy treatment * Discharged home following ED visit, observation, or inpatient stay * Enrolled in MyChart with valid mobile number and language preference recorded (English or Spanish) Exclusion Criteria: * Not enrolled in MyChart or lacking a valid mobile phone number. * Language preference not recorded or not English/Spanish (if messaging is only available in these languages). * Receiving hospice or palliative care services, where acute symptom management goals may differ. * Patients admitted directly to inpatient care without ED visit
References
Publications (0)
Data not yet available